## The Listing of Claims with Claim Amendments

This listing of claims will replace all prior versions of the claims in this application:

- 1. (Original) A medical article comprising an implantable substrate having a coating, the coating including a polymeric product of a reaction between a first reagent, a second reagent, and a third reagent, wherein:
- (a) the first reagent is selected from a group consisting of compounds having formulae (1), (2), (3), and (4):

O O 
$$\| \| \| \|$$
 (2) HO-R<sub>2</sub>-C-NH-Y-NH-C-R<sub>2</sub>-OH

$$HO-X-OH$$
 (3)

$$H_2N-Y-NH_2 \tag{4}$$

(b) the second reagent is selected from a group consisting of compounds having formulae (5), (6), (7), and (8):

O O 
$$\| \|$$
  $\|$  (6) HO-R<sub>2</sub>-C-NH-R<sub>4</sub>-NH-C-R<sub>2</sub>-OH

$$HO-R_4-OH$$
 (7)

$$H_2N-R_4-NH_2 \tag{8}$$

(c) the third reagent is a dicarboxylic acid having the formula (9):

wherein:

$$\begin{array}{cccc}
O & O \\
\parallel & \parallel \\
HO-C-R_3-C-OH
\end{array}$$
(9)

R<sub>1</sub> is hydrogen, methyl, iso-propyl, sec-butyl; iso-butyl, or benzyl group;

R<sub>2</sub> is methylene, methylene, n-propylene, iso-propylene, ethylmethylene, n-butylene, iso-butylene, sec-butylene, or n-amylene group;

 $R_3$  is a straight chained or branched aliphatic alkylene group  $C_nH_{2n}$ , wherein n is an integer between 2 and 12;

R<sub>4</sub> is a moiety derived from a compound selected from a group consisting of poly(ethylene glycol), poly(propylene glycol), random poly(ethylene glycol-co-propylene glycol), poly(ethylene glycol)-block-poly(propylene glycol), hyaluronic acid, poly(2-hydroxyethyl methacrylate), poly(3-hydroxypropylmethacrylamide), poly(styrene sulfonate), poly(vinyl pyrrolidone), and cellulosics;

X is a straight chained or branched aliphatic alkylene group  $C_nH_{2n}$ , wherein n is an integer between 2 and 12; and

Y is a straight chained or branched aliphatic alkylene group  $C_nH_{2n}$ , wherein n is 1, 2, or 5.

- 2. (Original) The medical article of Claim 1, wherein the implantable substrate is a stent.
- 3. (Currently Amended) The medical article of Claim 1, wherein the compound of formula (1) is a diol-diamine, and wherein the diol-diamine is a product of condensation of an amino acid and a diol.
- 4. (Original) The medical article of Claim 3, wherein the amino acid has the formula (10):

$$H_2N$$
— $CHR_1$ — $COOH$ . (10)

- 5. (Original) The medical article of Claim 3, wherein the amino acid is selected from a group consisting of glycine, alanine, valine, isoleucine, leucine, and phenyl alanine.
- 6. (Original) The medical article of Claim 3, wherein a diol is selected from a group consisting of ethylene glycol, 1,3-propanediol, 1,4-butane diol, 1,5-pentanediol, 1,6-hexanediol, 1,7-heptanediol, 1,8-octanediol, 1,9-nonanediol, 1,10-decanediol, 1,11-undecanediol, and 1,12-dodecanediol.
- 7. (Currently Amended) The medical article of Claim 1, wherein the compound of formula (2) is an amidediol, and wherein the amidediol is a product of condensation of a hydroxy acid and a diamine.
- 8. (Original) The medical article of Claim 7, wherein the hydroxy acid has the formula (11):

$$HO-R_2-COOH.$$
 (11)

- 9. (Original) The medical article of Claim 7, wherein the hydroxy acid is selected from a group consisting of glycolic acid, lactic acid,  $\beta$ -hydroxybutyric acid,  $\alpha$ -hydroxyvaleric acid, and  $\epsilon$ -hydroxycaproic acid.
- 10. (Original) The medical article of Claim 7, wherein the diamine is selected from a group consisting of putrescine, 1,2-ethanediamine, and cadavarene.
- 11. (Original) The medical article of Claim 1, wherein the compound of formula (3) is selected from a group consisting of ethylene glycol, 1,3-propanediol, 1,4-butanediol, 1,5-pentanediol, 1,6-hexanediol, 1,7-heptanediol, 1,8-octanediol, 1,9-nonanediol, 1,10-decanediol, 1,11-undecanediol, and 1,12-dodecanediol.

- 12. (Original) The medical article of Claim 1, wherein the compound of formula (4) is selected from a group consisting of putrescine, 1,2-ethanediamine, and cadavarene.
- 13. (Original) The medical article of Claim 1, wherein the compound of formula (5) is a PEG-diester-diamine conjugate, the conjugate is a product of condensation of an amino acid and poly(ethylene glycol).
- 14. (Original) The medical article of Claim 13, wherein the amino acid has the formula (10):

$$H_2N$$
— $CHR_1$ — $COOH$ . (10)

- 15. (Original) The medical article of Claim 13, wherein the amino acid is selected from a group consisting of glycine, alanine, valine, isoleucine, leucine, phenyl alanine, tyrosine, serine, and glutamic acid.
- 16. (Original) The medical article of Claim 1, wherein the compound of formula (6) is a PEG-amidediol conjugate, the conjugate is a product of condensation of a hydroxy acid and PEG-diamine.
- 17. (Original) The medical article of Claim 16, wherein the hydroxy acid has the formula (11):

$$HO-R_2-COOH.$$
 (11)

18. (Original) The medical article of Claim 17, wherein the hydroxy acid is selected from a group consisting of glycolic acid, lactic acid,  $\beta$ -hydroxybutyric acid,  $\alpha$ -hydroxyvaleric acid, and  $\epsilon$ -hydroxycaproic acid.

19. (Currently Amended) A medical article comprising an implantable substrate having a coating, wherein the coating includes a copolymer having a general formula (12) or (13):

$$-[M-P]_m-[M-Q]_n-$$
 (12)

$$-[M_1-P]_p$$
 (13)

wherein:

M is a moiety represented by the structure having the formula (14)

$$\begin{array}{cccc}
O & O \\
\parallel & \parallel \\
-C-R_3-C-
\end{array} \tag{14}$$

P is a moiety selected from a group consisting of structures having the formulae (15), (16), (17), and (18):

$$-0-X-0-$$
 (17)

$$-NH-Y-NH-$$
 (18)

Q is a moiety selected from a group consisting of structures having the formulae (19), (20), and (21)

$$-O-Z-O-$$
, and  $-NH-Z-NH-$  (21)

 $M_1$  is a moiety represented by the structure having the formula (22):

R<sub>1</sub> is hydrogen, methyl, iso-propyl, sec-butyl; iso-butyl, or benzyl group;

R<sub>2</sub> is methylene, methylene, n-propylene, iso-propylene, ethylmethylene, n-butylene, iso-butylene, sec-butylene, or n-amylene group;

 $R_3$  is a straight chained or branched aliphatic alkylene group  $C_nH_{2n}$ , wherein n is an integer between 2 and 12;

X is a straight chained or branched aliphatic alkylene group  $C_nH_{2n}$ , wherein n is an integer between 2 and 12;

Y is a straight chained or branched aliphatic alkylene group  $C_nH_{2n}$ , wherein n is 1, 2, or 5;

Z is a moiety derived from a compound selected from a group consisting of poly(ethylene glycol), poly(propylene glycol), random poly(ethylene glycol-co-propylene glycol), poly(ethylene glycol)-block-poly(propylene glycol), hyaluronic acid, poly(2-hydroxyethyl methacrylate), poly(3-hydroxypropylmethacrylamide), poly(styrene sulfonate), poly(vinyl pyrrolidone, and cellulosics; and

m, n, and p are integers where the value of m is between 5 and 1,800, the value of n is between 1 and 800 and the value of p is between 4 and 1,500.

20. (Currently Amended) The medical article of Claim 19, wherein the polymer is selected from a group consisting of copolymers of formulae (23), (24), (25), (26), (27), (28), (29), (30), (31), (32), (33), (34), (35), (36), (37), (38), (39), (40), (41), (42), and (43):

$$\begin{pmatrix} CH_{3}-CH-CH_{3} & CH_{3}-CH-CH_{3} & CH_{3}-CH-CH_{3} & CH_{3}-CH-CH_{3} \\ O & O & CH_{2} & O & O & CH_{2} \\ \parallel & \parallel & \parallel & \parallel & \parallel & \parallel & \parallel \\ C-(CH_{2})\frac{1}{8}C-NH-CH-C-O-(CH_{2})\frac{1}{6}O-C-CH-NH \\ \parallel & \parallel & \parallel & \parallel & \parallel \\ m \end{pmatrix} \begin{pmatrix} CH_{3}-CH-CH_{3} & CH_{3}-CH-CH_{3} \\ O & O & CH_{2} & 0 \\ \parallel & \parallel & \parallel & \parallel \\ C-(CH_{2})\frac{1}{8}C-NH-CH-C-O-PEG_{300}O-C-CH-NH \\ \parallel & \parallel & \parallel & \parallel \\ m \end{pmatrix}$$

(24),

(25),

(26),

(27),

(28),

(29),

(30),

$$\begin{bmatrix} O & O & CH_b & O & O & CH_b \\ C - CH_b - C - O - CH - C - NH + CH_b - 4NH - C - CH - O \end{bmatrix}_{m} \begin{bmatrix} O & O & O \\ C - CH_b - C - NH - PEG_W - NH - NH - C - CH - O \end{bmatrix}_{m}$$

(31),

(32),

(34),

(35),

(36),

(37),

(38),

$$\begin{bmatrix}
O & O & CH_3 & O & O & CH_3 \\
\parallel & \parallel & \parallel & \parallel & \parallel & \parallel \\
C - PEG_{1000} & C - NH - CH - C - O - (CH_2)_{4} & O - C - CH - NH
\end{bmatrix}_{p}$$

(39),

(40),

(41),

(42), and

(43);

where m and n are integers, and w is a molecular weight ranging from about 100 to about 4,000 Daltons.

- 21. (Currently Amended) A method for fabricating a medical article, the method including comprising synthesizing a copolymer and forming a coating based on the copolymer on at least a portion of an implantable substrate, wherein the synthesizing of the copolymer including comprises reacting a first reagent with a second reagent and with a third reagent, wherein:
- (a) the first reagent is selected from a group consisting of compounds having formulae (1), (2), (3), and (4):

O O 
$$\| \| \| \|$$
 (2) HO-R<sub>2</sub>-C-NH-Y-NH-C-R<sub>2</sub>-OH

$$HO-X-OH$$
 (3)

$$H_2N-Y-NH_2 \tag{4}$$

(b) the second reagent is selected from a group consisting of compounds having formulae (5), (6), (7), and (8):

O O 
$$\parallel$$
  $\parallel$   $\parallel$  (6) HO-R<sub>2</sub>-C-NH-R<sub>4</sub>-NH-C-R<sub>2</sub>-OH

$$HO-R_4-OH$$
 (7)

$$H_2N-R_4-NH_2 \tag{8}$$

(c) the third reagent is a dicarboxylic acid having the formula (9):

$$\begin{array}{ccc}
O & O \\
\parallel & \parallel \\
HO-C-R_2-C-OH
\end{array}$$
(9)

wherein:

R<sub>1</sub> is hydrogen, methyl, iso-propyl, sec-butyl; iso-butyl, or benzyl group;

R<sub>2</sub> is methylene, methylene, n-propylene, iso-propylene, ethylmethylene, n-butylene, iso-butylene, sec-butylene, or n-amylene group;

 $R_3$  is a straight chained or branched aliphatic alkylene group  $C_nH_{2n}$ , wherein n is an integer between 2 and 12;

R<sub>4</sub> is a moiety derived from a compound selected from a group consisting of poly(ethylene glycol), poly(propylene glycol), random poly(ethylene glycol-co-propylene glycol), poly(ethylene glycol)-block-poly(propylene glycol), hyaluronic acid, poly(2-hydroxyethyl methacrylate), poly(3-hydroxypropylmethacrylamide), poly(styrene sulfonate), poly(vinyl pyrrolidone), and cellulosics;

X is a straight chained or branched aliphatic alkylene group  $C_nH_{2n}$ , wherein n is an integer between 2 and 12;

Y is a straight chained or branched aliphatic alkylene group  $C_nH_{2n}$ , wherein n is 1, 2, or 5.

- 22. (Original) The method of Claim 21, wherein the implantable substrate is a stent.
- 23. (Original) The method of Claim 21, wherein the molar ratio between the first reagent, the second reagent, and the third reagent is about 1:1:2.
- 24. (Original) The method of Claim 21, wherein the compound of formula (1) is a diol-diamine, the diol-diamine is a product of condensation of an amino acid and a diol.
  - 25. (Original) The method of Claim 24, wherein the amino acid has the formula (10):

    H<sub>2</sub>N-CHR<sub>1</sub>-COOH. (10)
- 26. (Original) The method of Claim 24, wherein the amino acid is selected from a group consisting of glycine, alanine, valine, isoleucine, leucine, and phenyl alanine.
- 27. (Original) The method of Claim 24, wherein a diol is selected from a group consisting of ethylene glycol, 1,3-propanediol, 1,4-butane diol, 1,5-pentanediol, 1,6-hexanediol, 1,7-heptanediol, 1,8-octanediol, 1,9-nonanediol, 1,10-decanediol, 1,11-undecanediol, and 1,12-dodecanediol.
- 28. (Original) The method of Claim 21, wherein the compound of formula (2) is an amidediol, the amidediol is a product of condensation of a hydroxy acid and a diamine.
- 29. (Original) The method article of Claim 28, wherein the hydroxy acid has the formula (11):

$$HO-R_2-COOH.$$
 (11)

- 30. (Original) The method of Claim 28, wherein the hydroxy acid is selected from a group consisting of glycolic acid, lactic acid,  $\beta$ -hydroxybutyric acid,  $\alpha$ -hydroxyvaleric acid, and  $\epsilon$ -hydroxycaproic acid.
- 31. (Original) The method of Claim 28, wherein the diamine is selected from a group consisting of putrescine, 1,2-ethanediamine, and cadavarene.
- 32. (Original) The method of Claim 21, wherein the compound of formula (3) is selected from a group consisting of ethylene glycol, 1,3-propanediol, 1,4-butane diol, 1,5-pentanediol, 1,6-hexanediol, 1,7-heptanediol, 1,8-octanediol, 1,9-nonanediol, 1,10-decanediol, 1,11-undecanediol, and 1,12-dodecanediol.
- 33. (Original) The method of Claim 21, wherein the compound of formula (4) is selected from a group consisting of putrescine, 1,2-ethanediamine, and cadavarene.
- 34. (Original) The method of Claim 21, wherein the compound of formula (5) is a PEG-diester-diamine conjugate, the conjugate is a product of condensation of an amino acid and poly(ethylene glycol).
  - 35. (Original) The method of Claim 34, wherein the amino acid has the formula (10):

    H<sub>2</sub>N-CHR<sub>1</sub>-COOH. (10)
- 36. (Original) The method of Claim 34, wherein the amino acid is selected from a group consisting of glycine, alanine, valine, isoleucine, leucine, phenyl alanine, tyrosine, serine, and glutamic acid.

- 37. (Original) The method of Claim 21, wherein the compound of formula (6) is a PEG-amidediol conjugate, the conjugate is a product of condensation of a hydroxy acid and PEG-diamine.
- 38. (Original) The method of Claim 37, wherein the hydroxy acid has the formula (11):

$$HO-R_2-COOH.$$
 (11)

- 39. (Original) The method of Claim 37, wherein the hydroxy acid is selected from a group consisting of glycolic acid, lactic acid,  $\beta$ -hydroxybutyric acid,  $\alpha$ -hydroxyvaleric acid, and  $\epsilon$ -hydroxycaproic acid.
- 40. (Original) A method for fabricating a medical article, the method including synthesizing a copolymer and forming a coating based on the copolymer on at least a portion of an implantable substrate, wherein the copolymer has a general formula (12) or (13):

$$-[M-P]_{m}-[M-Q]_{n}-$$
 (12)

$$-[M_1-P]_p$$
 (13)

wherein:

M is a moiety represented by the structure having the formula (14)

$$\begin{array}{cccc}
O & O \\
\parallel & \parallel \\
-C-R_3-C-
\end{array} (14)$$

P is a moiety selected from a group consisting of structures having the formulae (15), (16), (17), and (18):

$$-O-X-O-$$
 (17)

$$-NH-Y-NH-$$
 (18)

Q is a moiety selected from a group consisting of structures having the formulae (19), (20), and (21)

$$-O-Z-O-$$
, and  $-NH-Z-NH-$  (21)

 $M_1$  is a moiety represented by the structure having the formula (22):

$$\begin{array}{cccc}
0 & 0 \\
\parallel & \parallel \\
-C & 7 & C
\end{array}$$
(22)

R<sub>1</sub> is hydrogen, methyl, iso-propyl, sec-butyl; iso-butyl, or benzyl group;

R<sub>2</sub> is methylene, methylene, n-propylene, iso-propylene, ethylmethylene, n-butylene, iso-butylene, sec-butylene, or n-amylene group;

 $R_3$  is a straight chained or branched aliphatic alkylene group  $C_nH_{2n}$ , wherein n is an integer between 2 and 12;

X is a straight chained or branched aliphatic alkylene group  $C_nH_{2n}$ , wherein n is an integer between 2 and 12;

Y is a straight chained or branched aliphatic alkylene group  $C_nH_{2n}$ , wherein n is 1, 2, or 5; and

Z is a moiety derived from a compound selected from a group consisting of poly(ethylene glycol), poly(propylene glycol), random poly(ethylene glycol-co-propylene glycol), poly(ethylene glycol)-block-poly(propylene glycol), hyaluronic acid, poly(2-hydroxyethyl methacrylate), poly(3-hydroxypropylmethacrylamide), poly(styrene sulfonate), poly(vinyl pyrrolidone, and cellulosics; and

m, n, and p are integers where the value of m is between 5 and 1,800, the value of n is between 1 and 800 and the value of p is between 4 and 1,500.

41. (Currently amended) The method of Claim 40, wherein the copolymer is selected from a group consisting of copolymers of formulae (23), (24), (25), (26), (27), (28), (29), (30), (31), (32), (33), (34), (35), (36), (37), (38), (39), (40), (41), (42), and (43):

(23),

$$\begin{bmatrix} O & O & CH_3 & O & O & CH_3 \\ -C-(CH_2) + C-NH-CH-C-O-(CH_2) + O-C-CH-NH \\ 2 \end{bmatrix} \begin{bmatrix} O & O & CH_3 & O & O & CH_3 \\ -C-(CH_2) + C-NH-CH-C-O-PEG_W^{-}O-C-CH-NH \\ 2 \end{bmatrix} \begin{bmatrix} O & O & CH_3 & O & O & CH_3 \\ -C-(CH_2) + C-NH-CH-C-O-PEG_W^{-}O-C-CH-NH \\ 2 \end{bmatrix} \begin{bmatrix} O & O & CH_3 & O & O & CH_3 \\ -C-(CH_2) + C-NH-CH-C-O-PEG_W^{-}O-C-CH-NH \\ 2 \end{bmatrix} \begin{bmatrix} O & O & CH_3 & O & O & CH_3 \\ -C-(CH_2) + C-NH-CH-C-O-PEG_W^{-}O-C-CH-NH \\ 2 \end{bmatrix} \begin{bmatrix} O & O & CH_3 & O & O & CH_3 \\ -C-(CH_2) + C-NH-CH-C-O-PEG_W^{-}O-C-CH-NH \\ 2 \end{bmatrix} \begin{bmatrix} O & O & CH_3 & O & O & CH_3 \\ -C-(CH_2) + C-NH-CH-C-O-PEG_W^{-}O-C-CH-NH \\ 2 \end{bmatrix} \begin{bmatrix} O & O & CH_3 & O & O & CH_3 \\ -C-(CH_2) + C-NH-CH-C-O-PEG_W^{-}O-C-CH-NH \\ 2 \end{bmatrix} \begin{bmatrix} O & O & CH_3 & O & O & CH_3 \\ -C-(CH_2) + C-NH-CH-C-O-PEG_W^{-}O-C-CH-NH \\ 2 \end{bmatrix} \begin{bmatrix} O & O & CH_3 & O & O & CH_3 \\ -C-(CH_2) + C-NH-CH-C-O-PEG_W^{-}O-C-CH-NH \\ 2 \end{bmatrix} \begin{bmatrix} O & O & CH_3 & O & O & CH_3 \\ -C-(CH_2) + C-NH-CH-C-O-PEG_W^{-}O-C-CH-NH \\ 2 \end{bmatrix} \begin{bmatrix} O & O & CH_3 & O & O & CH_3 \\ -C-(CH_2) + C-NH-CH-C-O-PEG_W^{-}O-C-CH-NH \\ 2 \end{bmatrix} \begin{bmatrix} O & O & CH_3 & O & O & CH_3 \\ -C-(CH_2) + C-NH-CH-C-O-PEG_W^{-}O-C-CH-NH \\ 2 \end{bmatrix} \begin{bmatrix} O & O & CH_3 & O & O & CH_3 \\ -C-(CH_2) + C-NH-CH-C-O-PEG_W^{-}O-C-CH-NH \\ 2 \end{bmatrix} \begin{bmatrix} O & O & CH_3 & O & O & CH_3 \\ -C-(CH_2) + C-NH-CH-C-O-PEG_W^{-}O-C-C-CH-NH \\ 2 \end{bmatrix} \begin{bmatrix} O & O & CH_3 & O & O & CH_3 \\ -C-(CH_2) + C-NH-CH-C-O-PEG_W^{-}O-C-C-CH-NH \\ 2 \end{bmatrix} \begin{bmatrix} O & O & CH_3 & O & O & CH_3 \\ -C-(CH_2) + C-NH-CH-C-O-PEG_W^{-}O-C-C-CH-NH \\ 2 \end{bmatrix} \begin{bmatrix} O & O & CH_3 & O & O & CH_3 \\ -C-(CH_2) + C-NH-CH-C-O-PEG_W^{-}O-C-C-CH-NH \\ 2 \end{bmatrix} \begin{bmatrix} O & O & CH_3 & O & O & CH_3 \\ -C-(CH_2) + C-NH-CH-C-O-PEG_W^{-}O-C-C-CH-NH \\ 2 \end{bmatrix} \begin{bmatrix} O & O & CH_3 & O & O & CH_3 \\ -C-(CH_2) + C-NH-CH-C-O-PEG_W^{-}O-C-C-CH-NH \\ 2 \end{bmatrix} \begin{bmatrix} O & O & CH_3 & O & O & CH_3 \\ -C-(CH_2) + C-NH-CH-C-O-PEG_W^{-}O-C-C-CH-NH \\ 2 \end{bmatrix} \begin{bmatrix} O & O & CH_3 & O & O & CH_3 \\ -C-(CH_2) + C-NH-CH-C-O-PEG_W^{-}O-C-C-CH-NH \\ 2 \end{bmatrix} \begin{bmatrix} O & O & CH_3 & O & O & CH_3 \\ -C-(CH_2) + C-NH-CH-C-O-PEG_W^{-}O-C-C-CH-NH \\ 2 \end{bmatrix} \begin{bmatrix} O & O & CH_3 & O & O & CH_3 \\ -C-(CH_2) + C-NH-C-C-C-CH-NH \\ 2 \end{bmatrix} \begin{bmatrix} O & O & CH_3 & O & O & CH_3 \\ -C-(CH_2) + C-NH-C-C-C-C-CH-NH \\ 2 \end{bmatrix} \begin{bmatrix} O & O & CH_3 & O & O & C$$

$$\begin{bmatrix} \text{CH}_{\text{0}} - \text{CH}_{\text{-}} \text{CH}_{\text{0}} & \text{CH}_{\text{0}} - \text{CH}_{\text{-}} \text{CH}_{$$

(26),

(27),

(28),

(29),

(30),

(31),

(32),

(34).

(35),

(38),

$$\begin{bmatrix}
O & O & CH_3 & O & O & CH_3 \\
\parallel & \parallel & \parallel & \parallel & \parallel & \parallel \\
C - PEG_{1000} & C - NH - CH - C - O - (CH_2)_4 & O - C - CH - NH
\end{bmatrix}$$
p

(39),

$$\begin{bmatrix} O & O & CH_{3}O & O & CH_{3} \\ C & CH_{2} & C & NH - CH - C - O - (CH_{2})_{+} & O - C - CH - NH \\ C & CH_{2} & C & NH - CH - C - O - (CH_{2})_{+} & O - C - CH - NH \\ C & CH_{2} & C & NH - CH - C - O - (CH_{2})_{+} & O & CH_{3} \\ C & CH_{2} & C & NH - CH - C - O - (CH_{2})_{+} & O & CH_{3} \\ C & CH_{2} & C & NH - CH - C - O - (CH_{2})_{+} & O & CH_{3} \\ C & CH_{2} & C & NH - CH - C - O - (CH_{2})_{+} & O - C - CH - NH \\ C & CH_{2} & C - NH - CH - C - O - PEG - O - C - CH - NH \\ M & NH - CH - C - O - CH_{2} & NH_{2} & C - NH_{2} & C - NH_{2} & C - NH_{3} \\ NH & NH_{2} & C - NH_{3} & C - CH_{3} & C - CH_{3} & C - CH_{3} \\ NH_{3} & C - CH_{3} & C - CH_{3} & C - CH_{3} & C - CH_{3} \\ NH_{4} & C - CH_{2} & C - NH_{3} & C - CH_{3} & C - CH_{3} \\ NH_{4} & C - CH_{3} & C - CH_{3} & C - CH_{3} \\ NH_{4} & C - CH_{3} & C - CH_{3} & C - CH_{3} \\ NH_{4} & C - CH_{3} & C - CH_{3} & C - CH_{3} \\ NH_{4} & C - CH_{3} & C - CH_{3} & C - CH_{3} \\ NH_{4} & C - CH_{3} & C - CH_{3} & C - CH_{3} \\ NH_{4} & C - CH_{3} & C - CH_{3} \\ NH_{4} & C - CH_{3} & C - CH_{3} \\ NH_{4} & C - CH_{3} & C - CH_{3} \\ NH_{4} & C - CH_{3} & C - CH_{3} \\ NH_{4} & C - CH_{3} & C - CH_{3} \\ NH_{4} & C - CH_{3} & C - CH_{3} \\ NH_{4} & C - CH_{3} & C - CH_{3} \\ NH_{4} & C - CH_{3} & C - CH_{3} \\ NH_{4} & C - CH_{3} & C - CH_{3} \\ NH_{4} & C - CH_{3} & C - CH_{3} \\ NH_{4} & C - CH_{3} & C - CH_{3} \\ NH_{4} & C - CH_{3} & C - CH_{3} \\ NH_{4} & C - CH_{3} & C - CH_{3} \\ NH_{4} & C - CH_{3} & C - CH_{3} \\ NH_{4} & C - CH_{3} & C - CH_{4} \\ NH_{4} & C - CH_{4} & C - CH_{4} \\ NH_{4} & C - CH_{4} \\ NH_{4}$$

(41),

## (42), and

## (43);

where m and n are integers, and w is a molecular weight ranging from about 100 to about 4,000 Daltons.